Novel 3D platforms to engineer bone microtissues for in vitro disease models
Osteosarcoma is a rare but devastating bone tumour that mainly affects children, adolescents and elderly. This type of tumour is very resistant to therapy, being thus urgent to find new effective treatments. In vitro tumour models...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
AMNIOGEL
Extracellular matrix derived products from human placenta to...
150K€
Cerrado
CoDe4Bio
COmputational DEsign for 4D BIOfabrication: harnessing progr...
1M€
Cerrado
TissueEng
3D bioprinting construct for the diminishing of bone tumor a...
Cerrado
PID2020-113819RB-I00
DISEÑO DE IMPLANTES PARA TERAPIA TUMORAL Y REGENERACION OSEA...
151K€
Cerrado
PRINT-CHEMO
To develop 3D bioPRINTed osteoinductive constructs that deli...
258K€
Cerrado
Design2Guide
Cell-instructive matrices to deconstruct tumour tissues
150K€
Cerrado
Información proyecto MicroBone
Duración del proyecto: 18 meses
Fecha Inicio: 2018-02-06
Fecha Fin: 2019-08-31
Líder del proyecto
UNIVERSIDADE DE AVEIRO
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
150K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Osteosarcoma is a rare but devastating bone tumour that mainly affects children, adolescents and elderly. This type of tumour is very resistant to therapy, being thus urgent to find new effective treatments. In vitro tumour models can recapitulate many aspects of the natural tumour environment, and could be used to improve the predictive value of the effect of anticancer drug candidates. The aim of MicroBone is the development of biological relevant spherical-based 3D disease models that could be used as an enabling tool for personalized and precision drug discovery, increasing our understanding of the mechanisms behind bone cancer and testing new drug-based therapies.